Outcome of Board Meeting
Awaiting price reaction for this filing.
Board approved unaudited financial results for the quarter ended June 30, 2025. Standalone revenue from operations rose modestly to ₹6,450.12 lakhs from ₹6,102.45 lakhs in Q1FY25 (up ~5.7%), while standalone net loss narrowed sharply to ₹17.85 lakhs from ₹145.55 lakhs. On a consolidated basis, revenue fell about 21% YoY to ₹11,522.12 lakhs (from ₹14,582.81 lakhs) and net loss widened to ₹2,337.07 lakhs from ₹801.35 lakhs, dragged by the loss-making subsidiary Hindusthan Speciality Chemicals Ltd (HSCL). The company has signed a Share Purchase Agreement on June 12, 2025 to sell HSCL to DCM Shriram Limited, with completion expected in FY26. Statutory auditor K.N. Gutgutia & Co. issued a clean limited review report with no qualifications.
Standalone operations are improving with revenue growth and sharply reduced losses, but the consolidated picture remains weak due to HSCL's mounting losses. The planned divestment of HSCL to DCM Shriram is a major portfolio reshuffle that could materially reshape consolidated earnings once the sale closes in FY26.